Weight Loss Investigational

Oxyntomodulin

A gut hormone that acts on GLP-1 and glucagon-related pathways and helped shape the modern obesity-peptide conversation.

Gut HormoneGLP-1GlucagonObesityInvestigational

Also referenced as: OXM

Also appears in: Hormone

Status
Investigational

This compound has a genuine development or study trail, but it is not an approved routine drug.

Category
Weight Loss

Primary lane: Weight Loss. Also surfaces under Hormone for browsing and discovery.

Aliases
1

OXM

Signal depth
Medium

No FDA label signal · 54 trials · 493 PubMed results

Early
Research evidence

Oxyntomodulin has human trials registered, but none have reported controlled results yet. Most current claims about what it does in people rest on preclinical (lab or animal) work, not published human data.

Oxyntomodulin has 3 name-matched clinical trials (1 international) (highest phase: no phased trial) and 493 PubMed-indexed publications and is not FDA-approved.

🌍 1 international trial
Human data
Human (non-phased)
Trial quality
Randomized
Outcomes
Surrogate / early
Replication
Multiple trials
Literature
High-impact
Trial Oxyntomodulin, Mechanisms of Action in Relation to Appetite, Food Intake, Gastric Emptying and Energy Expenditure. NA · Randomized GLP-1 and Oxyntomodulin Release in Relation to Diet in Type 2 Diabetes Patients. ISRCTN Subcutaneous oxyntomodulin reduces body-weight in overweight subjects The Journal of Clinical Endocrinology & Metabolism · 474 citations Oxyntomodulin Suppresses Appetite and Reduces Food Intake in Humans Diabetes · 433 citations Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects Gastroenterology · 374 citations Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure
Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What oxyntomodulin is

Oxyntomodulin is an endogenous gut hormone with relevance to both GLP-1 and glucagon-related metabolic signaling.

Why it matters

It is one of the foundational physiology peptides behind many modern obesity-drug ideas, even when it is not the final commercial molecule people hear about.

Regulatory context

Oxyntomodulin is not FDA approved as a mainstream therapeutic peptide in the United States.

Practical reading note

Some peptides matter because they are marketed widely. Others matter because later blockbuster drugs were built on the physiology they helped define. Oxyntomodulin is in the second category.